Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$16.57 USD
-0.03 (-0.18%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.57 USD
-0.03 (-0.18%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $16.58 +0.01 (0.06%) 7:58 PM ET
4-Sell of 5 4
A Value B Growth C Momentum A VGM
Zacks News
ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.
Juno Therapeutics (JUNO) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Juno Therapeutics Inc. (JUNO) is set to report fourth-quarter 2016 results on Mar 1, after the market closes.
Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.
Endo (ENDP) to Post Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Endo International plc (ENDP) is scheduled to report fourth-quarter 2016 results on Feb 28, before the opening bell.
Exelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store?
by Zacks Equity Research
Exelixis, Inc. (EXEL) is scheduled to report fourth-quarter 2016 results on Feb 27, after the market close.
Intercept (ICPT) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) is scheduled to report fourth-quarter 2016 results on Feb 23.
Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.
Geron (GERN) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Geron Corporation (GERN) is expected to report fourth-quarter 2016 results next week. In the last reported quarter, the company recorded a positive earnings surprise of 66.67%.
Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?
by Zacks Equity Research
Ligand Pharmaceuticals Incorporated (LGND) is scheduled to report fourth-quarter 2016 results on Feb 23, after the market closes.
Implied Volatility Surging for Pacira Pharmaceuticals (PCRX) Stock Options
by Zacks Equity Research
Pacira Pharmaceuticals (PCRX) warrants investors' attention based on moves in the options market lately.
What's in Store for ImmunoGen (IMGN) this Earnings Season?
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) is scheduled to report results for the three months ended Dec 31, 2016 on Feb 17, before the opening bell. Overall, the company has posted an average negative surprise of 19.34%.
Will Zoetis (ZTS) Disappoint Estimates This Earnings Season?
by Zacks Equity Research
Zoetis Inc. (ZTS) is scheduled to report fourth-quarter and full year 2016 results on Feb 16 before the market opens.